Precision Medicine in Neurodegenerative Disorders Part II

Part 3 Basic Science Development1. Role of rodent models in advancing precision medicine for Parkinson disease2. The allure and pitfalls of the prion-like aggregation in neurodegeneration3. The shift to a proteinopenia paradigm in neurodegeneration4. Disease mechanisms as subtypes: Lysosomal dysfunction in the endolysosomal Parkinson disease subtype5. Disease mechanisms as subtypes: Mitochondrial and bioenergetic dysfunction 6. Disease mechanisms as subtypes: Immune dysfunction in Parkinson disease7. Disease mechanisms as subtypes: Inflammation in Parkinson disease and related disorders8. Disease mechanisms as subtypes: Microbiome 9. LRRK2: Genetic mechanisms vs genetic subtypes 10. Genetic mechanism vs genetic subtypes: The example of GBA 11. Subtyping monogenic disorders: Huntington disease Part 4 Clinical Trials and Therapeutic Approaches12. Disease-modifying vs symptomatic treatments: splitting over lumping13. Restorative cell and gene therapies for Parkinson disease14. The promise and challenges of extracellular vesicles in the diagnosis of neurodegenerative diseases15. Therapeutic potential of extracellular vesicles in neurodegenerative disorders16. Lessons from antiamyloid-ß immunotherapies in Alzheimer disease 17. Lessons from immunotherapies in multiple sclerosis 18. Adaptive clinical trials and master protocols19. Role of novel endpoints and evaluations of response in Parkinson Disease20. Leveraging the regulatory framework to facilitate drug development in Parkinson disease